Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease)

Neurological Sciences

Volumn 28, Issue 4, 2007, Pages 209-211

  Capobianco, Multipla ^a   Malucchi, S ^a   di Sapio, A ^a   Gilli, F ^a   Sala, A ^a   Bottero, R ^b   Marnetto, F ^a   Doriguzzi Bozzo, C ^b   Bertolotto, A ^a  

^a SAN LUIGI GONZAGA HOSPITAL   (Italy)

^b SOC Neurologia   (Italy)

Author keywords

Devic's disease; Neuromyelitis optica; Rituximab; Treatment

Indexed keywords

ANTIBODY; AQUAPORIN 4; BETA1A INTERFERON; CD19 ANTIGEN; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; REBIF 44; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; ANTIBODY DETECTION; ARTICLE; B LYMPHOCYTE; CASE REPORT; DRUG MEGADOSE; DRUG RESPONSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; IMMUNOTHERAPY; LYMPHOCYTE DEPLETION; MYELOOPTIC NEUROPATHY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMAPHERESIS; RELAPSE; SCORING SYSTEM; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; BRAIN; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MAGNETIC RESONANCE IMAGING; NEUROMYELITIS OPTICA; SPINAL CORD;

EID: 34547936733     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-007-0823-z     Document Type: Article

References (10)

1. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG (1999) The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 53:1107-1114
2. Ghezzi A, Bergamaschi R, Martinelli V et al and the Italian Devic's Study Group (IDESG) (2004) Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica. J Neurol 251:47-52
3. Lucchinetti CF, Mandler RN, McGavern D et al (2002) A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 125:1450-1461
4. Lennon VA, Wingerchuk DM, Kryzer TJ et al (2004) A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 364:2106-2112
5. Lennon VA, Kryzer TJ, Pittock SJ et al (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202:474-477
6. Wingerchuk DM, Weinshenker BG (2005) Neuromyelitis optica. Curr Treat Options Neurol 7:173-182
7. Cree BAC, Lamb S, Morgan K et al (2005) An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64:1270-1272
8. Wingerchuk DM, Lennon VA, Pittok SJ et al (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66:1485-1489
9. Lalive PH, Menge T, Barman I et al (2006) Identification of new serum autoantibodies in neuromyelitis optica using protein microarrays. Neurology 67:176-177
10. Weinstock-Guttman B, Ramanathan M, Lincoff N et al (2006) Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol 63:957-963